Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: Indian J Med Res)
Source: Indian J Med Res - April 5, 2024 Category: Research Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - April 5, 2024 Category: Biomedical Science Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: Indian J Med Res)
Source: Indian J Med Res - April 5, 2024 Category: Research Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - April 5, 2024 Category: Biomedical Science Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: Indian J Med Res)
Source: Indian J Med Res - April 5, 2024 Category: Research Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study
CONCLUSIONS: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.PMID:38577858 | PMC:PMC11050758 | DOI:10.4103/ijmr.ijmr_3459_21 (Source: The Indian Journal of Medical Research)
Source: The Indian Journal of Medical Research - April 5, 2024 Category: Biomedical Science Authors: Swati Chugh Goutam Panda Smruti Mokal Hasmukh Jain Bhausaheb Bagal Nehal Khanna Sridhar Epari Sachin Punatar Lingaraj Nayak Anant Gokarn Naveen Khattry Manju Sengar Siddhartha Laskar Jayant S Goda Source Type: research
Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies
AbstractLiquid biopsy is a minimally invasive diagnostic tool for identification of tumor-related mutations in circulating cell-free DNA (cfDNA). The aim of this study was to investigate feasibility, sensitivity, and specificity of non-invasive prenatal test (NIPT) for identification of chromosomal abnormalities in cfDNA from a total of 77 consecutive patients with non-Hodgkin B-cell lymphomas, Hodgkin lymphoma (HL), or plasma cell dyscrasia. In this case series, half of patients had at least one alteration, more frequently in chromosome 6 (23.1%), chromosome 9 (20.5%), and chromosomes 3 and 18 (16.7%), with losses of chro...
Source: Clinical and Experimental Medicine - April 5, 2024 Category: Research Source Type: research
Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials
CONCLUSIONS: In this combined analysis of 2 randomized phase 3 clinical trials, consolidative RT to initial sites of bulky nodal involvement was not associated with a PFS benefit in patients with advanced Hodgkin lymphoma in metabolic complete response after 2 and 6 cycles of doxorubicin, bleomycin, vinblastine and dacarbazine.PMID:38550369 | PMC:PMC10965437 | DOI:10.1016/j.adro.2024.101450 (Source: Adv Data)
Source: Adv Data - March 29, 2024 Category: Epidemiology Authors: Ryan T Hughes Niema B Razavian Rachel F Shenker Christopher R Kelsey Sydney Smith Ralph B D'Agostino Karen M Winkfield Source Type: research
Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials
CONCLUSIONS: In this combined analysis of 2 randomized phase 3 clinical trials, consolidative RT to initial sites of bulky nodal involvement was not associated with a PFS benefit in patients with advanced Hodgkin lymphoma in metabolic complete response after 2 and 6 cycles of doxorubicin, bleomycin, vinblastine and dacarbazine.PMID:38550369 | PMC:PMC10965437 | DOI:10.1016/j.adro.2024.101450 (Source: Adv Data)
Source: Adv Data - March 29, 2024 Category: Epidemiology Authors: Ryan T Hughes Niema B Razavian Rachel F Shenker Christopher R Kelsey Sydney Smith Ralph B D'Agostino Karen M Winkfield Source Type: research
Meta-Analysis of Incidence and Mortality of Firefighter Cancer: An Update on Emerging Science
CONCLUSIONS: The findings underscore the global cancer burden among firefighters, and indicate that geographically stratifying studies afford a more nuanced risk perspective. Further research should investigate why US firefighters exhibit higher cancer mortality rates compared to international counterparts.PMID:38546063 | DOI:10.31557/APJCP.2024.25.3.801 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - March 28, 2024 Category: Cancer & Oncology Authors: Sara A Jahnke Nattinee Jitnarin Christopher K Haddock Christopher Kaipust Walker S Carlos Poston Brittany S Hollerbach Carolyn Crisp Brittni Naylor Metoyer Source Type: research
